RESEARCH ARTICLE


The Pathophysiology of Antiphospholipid Syndrome



Pablo Ruiz Sada1, Hannah Cohen 2, David Isenberg3, *
1 Hospital Universitario de Basurto, Departamento de MedicinaInterna, Bilbao, Spain
2 University College London, London, UK
3 Centre for Rheumatology Research, Division of Medicine, University College London, London, UK


Article Metrics

CrossRef Citations:
2
Total Statistics:

Full-Text HTML Views: 7351
Abstract HTML Views: 2501
PDF Downloads: 1645
ePub Downloads: 706
Total Views/Downloads: 12203
Unique Statistics:

Full-Text HTML Views: 3386
Abstract HTML Views: 1268
PDF Downloads: 1113
ePub Downloads: 496
Total Views/Downloads: 6263



Creative Commons License
© Sada et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Centre for Rheumatology, UCL Division of Medicine, Room 424, Rayne Building, 5 University Street, WC1E 6JF, London, UK; Tel: 0203 108 2148; Fax: 0203 108 2152; E-mail d.isenberg@ucl.ac.uk


Abstract

Advances in our knowledge of the pathogenic mechanisms of antiphospholipid syndrome have been achieved in the past few years. Apart from the well-known role of anti-β2-glycoprotein I antibodies, complement, endocrine and genetic factors and a variety of other molecules are now under investigation. These new approaches should lead to novel explanations and potential new treatment options.

Keywords: Anti-β2-glycoprotein, antiphospholipid syndrome, antiphospholipid antibodies, complement.